Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's main brand continues to drive performance growth, with a revenue increase of 30.8% year-on-year in H1 2025, reaching 1.769 billion yuan, while net profit grew by 5.2% [4][5] - The company has adjusted its profit forecast due to intense industry competition, projecting net profits of 400 million, 523 million, and 667 million yuan for 2025, 2026, and 2027 respectively [4][5] - The dual-brand strategy is expected to sustain performance growth, and the current valuation is considered reasonable [4] Financial Performance - In H1 2025, the company achieved revenue of 1.769 billion yuan, with a net profit of 186 million yuan [4] - For Q2 2025, revenue was 923 million yuan (up 33.5%), but net profit decreased by 23.1% to 51 million yuan [4] - The company's gross margin for H1 2025 was 74.6%, remaining stable year-on-year [5] Product and Market Strategy - The company reported strong performance in eye care products, with revenue of 420 million yuan (up 76.2%), while skincare and beauty categories also showed growth [5] - The online sales channel saw a significant increase, with online revenue reaching 1.571 billion yuan (up 37.9%), while offline sales declined by 7.1% [5] - The company is focusing on enhancing brand awareness and product innovation, with a notable new product launch achieving top sales rankings [6] Financial Projections - Revenue projections for 2025 to 2027 are 3.852 billion, 4.852 billion, and 5.906 billion yuan respectively, with year-on-year growth rates of 29.7%, 26.0%, and 21.7% [7][9] - The projected net profit for 2025 is 400 million yuan, with an expected EPS of 1.00 yuan [7][9] - The company's P/E ratio is projected to decrease from 45.4 in 2025 to 27.2 in 2027, indicating improving valuation over time [7][9]

Group 1 - The company reported its main operational data for Q2 2025, including production, sales, and revenue figures for its key products [1][2] - The total production and sales figures for the main product categories are as follows: Eye products (1,417,633 produced, 1,293,001 sold, revenue of 206,219,439 yuan), Skincare products (4,321,217 produced, 4,012,166 sold, revenue of 364,708,224 yuan), Cleansing products (1,248,862 produced, 1,089,700 sold, revenue of 65,706,024 yuan), and Beauty products (2,942,370 produced, 3,173,964 sold, revenue of 268,017,038 yuan) [1] - The average selling price of eye products increased by 57.93% to 159.49 yuan due to a higher proportion of upgraded eye cream sales and a lower proportion of eye mask sales [1][2] Group 2 - The average selling price of beauty products increased by 42.78% to 84.44 yuan, attributed to optimized marketing strategies that reduced low-priced promotional items [2] - The company experienced a decrease in the prices of key raw materials, including propylene glycol and butylene glycol, which helped lower procurement costs by 2% [2] - The company implemented large-scale procurement strategies, resulting in a 10% decrease in packaging materials, a 15% decrease in tube packaging, and a 24% decrease in certain box packaging materials [2]

证券代码：603983 证券简称：丸美生物 公告编号：2025-020 广东丸美生物技术股份有限公司 关于2025年第二季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将公司 2025 年第二季度主要经营数据 披露如下： 二、2025 年第二季度公司主要产品和原材料的价格变动情况 （一）主要产品价格变动情况 眼部类产品平均售价上升原因：主要系本期售价较高的眼霜产品升级销售占 比提升以及售价较低的眼膜产品销售占比下降所致。 美容类产品平均售价上升原因：主要系本期优化了营销策略，减少了低价引 主要产品 产量（支） 销量（支） 营业收入（元） 眼部类 1,417,633 1,293,001 206,219,439 护肤类 4,321,217 4,012,166 364,708,224 洁肤类 1,248,862 1,089,700 65,706,024 美容类 2,942,370 3,173,96 ...